Long-term successful control of super-multidrug-resistant human immunodeficiency virus type 1 infection by a novel combination therapy of raltegravir, etravirine, and boosted-darunavir

Journal of Infection and Chemotherapy

Volumn 17, Issue 1, 2011, Pages 105-110

  Nakamura, Hitomi ^a   Miyazaki, Naoko ^a,b   Hosoya, Noriaki ^a   Koga, Michiko ^a   Odawara, Takashi ^a   Kikuchi, Tadashi ^a   Koibuchi, Tomohiko ^a   Kawana Tachikawa, Ai ^a   Fujii, Takeshi ^a   Miura, Toshiyuki ^a   Iwamoto, Aikichi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b The Japan Foundation   (Japan)

Author keywords

Antiretrovirals; Darunavir; Drug resistance; Etravirine; Human immunodeficiency virus type 1; Raltegravir; Salvage therapy

Indexed keywords

DARUNAVIR; ENFUVIRTIDE; ETRAVIRINE; INDINAVIR; LAMIVUDINE; NELFINAVIR; RALTEGRAVIR; STAVUDINE; ZIDOVUDINE;

ADULT; ARTICLE; CASE REPORT; CD4 LYMPHOCYTE COUNT; COMBINATION CHEMOTHERAPY; DRUG POTENCY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFECTION CONTROL; LONG TERM CARE; MALE; MALE HOMOSEXUAL; MULTIDRUG RESISTANCE; NONHUMAN; NUCLEOTIDE SEQUENCE; RASH; SALVAGE THERAPY; VIRUS MUTATION; VIRUS REPLICATION;

EID: 79951558288     PISSN: 1341321X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10156-010-0082-4     Document Type: Article

References (21)

1. J Bailey JN Blankson M Wind-Rotolo RF Siliciano 2004 Mechanisms of HIV-1 escape from immune responses and antiretroviral drugs Curr Opin Immunol 16 470 476 1:CAS:528:DC%2BD2cXlsFyrtb4%3D 10.1016/j.coi.2004.05.005 15245741 (Pubitemid 38881675)
2. C de Mendoza Gallego O V Soriano 2002 Mechanisms of resistance to antiretroviral drugs-clinical implications AIDS Rev 4 64 82 12152520 (Pubitemid 34808782)
3. DR Kuritzkes 2007 HIV resistance: frequency, testing, mechanisms Top HIV Med 15 150 154 18073450
4. B Grinsztejn BY Nguyen C Katlama JM Gatell A Lazzarin D Vittecoq, et al. 2007 Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial Lancet 369 1261 1269 1:CAS:528:DC%2BD2sXktF2hu7c%3D 10.1016/S0140-6736(07)60597-2 17434401 (Pubitemid 46553846)
5. RT Steigbigel DA Cooper PN Kumar JE Eron M Schechter M Markowitz, et al. 2008 Raltegravir with optimized background therapy for resistant HIV-1 infection N Engl J Med 359 339 354 10.1056/NEJMoa0708975 18650512
6. A Lazzarin T Campbell B Clotet M Johnson C Katlama A Moll, et al. 2007 Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial Lancet 370 39 48 1:CAS:528: DC%2BD2sXnsFWmtLg%3D 10.1016/S0140-6736(07)61048-4 17617271 (Pubitemid 47017467)
7. JV Madruga P Cahn B Grinsztejn R Haubrich J Lalezari A Mills, et al. 2007 Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial Lancet 370 29 38 1:CAS:528: DC%2BD2sXnsFWmtLs%3D 10.1016/S0140-6736(07)61047-2 17617270 (Pubitemid 47017466)
8. JM Molina C Cohen C Katlama B Grinsztejn A Timerman J Pedro Rde, et al. 2007 Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced patients: 24-week results of POWER 3 J Acquir Immune Defic Syndr 46 24 31 1:CAS:528:DC%2BD2sXhtFSis77N 17621237 (Pubitemid 47514614)
9. JM Molina A Hill 2007 Darunavir (TMC114): a new HIV-1 protease inhibitor Expert Opin Pharmacother 8 1951 1964 1:CAS:528:DC%2BD2sXhtVGjs73L 10.1517/14656566.8.12.1951 17696796 (Pubitemid 47316150)
10. E Poveda C de Mendoza L Martin-Carbonero A Corral V Briz J Gonzalez-Lahoz, et al. 2007 Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitors J Antimicrob Chemother 60 885 888 1:CAS:528:DC%2BD2sXht1ygtbnL 10.1093/jac/dkm276 17646201 (Pubitemid 47434272)
11. E Poveda C Garrido C de Mendoza A Corral J Cobo J Gonzalez-Lahoz, et al. 2007 Prevalence of etravirine (TMC-125) resistance mutations in HIV-infected patients with prior experience of non-nucleoside reverse transcriptase inhibitors J Antimicrob Chemother 60 1409 1410 1:CAS:528:DC%2BD2sXhtlKmtL%2FE 10.1093/jac/dkm372 17913723 (Pubitemid 350168348)
12. F Damond B Roquebert A Benard G Collin M Miceli P Yeni, et al. 2007 Human immunodeficiency virus type 1 (HIV-1) plasma load discrepancies between the Roche COBAS AMPLICOR HIV-1 MONITOR Version 1.5 and the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 assays J Clin Microbiol 45 3436 3438 1:STN:280:DC%2BD2srptFKktg%3D%3D 10.1128/JCM.00973-07 17715371 (Pubitemid 47585682)
13. JD Yao JJ Germer F Damond B Roquebert D Descamps 2008 Plasma load discrepancies between the Roche Cobas Amplicor human immunodeficiency virus type 1 (HIV-1) Monitor version 1.5 and Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 assays J Clin Microbiol 46 834 10.1128/JCM.02144-07 18252859 author reply 834
14. M Schutten D Peters NK Back M Beld K Beuselinck V Foulongne, et al. 2007 Multicenter evaluation of the new Abbott RealTime assays for quantitative detection of human immunodeficiency virus type 1 and hepatitis C virus RNA J Clin Microbiol 45 1712 1717 1:CAS:528:DC%2BD2sXnsVKrt7c%3D 10.1128/JCM.02385-06 17409216 (Pubitemid 46933896)
15. LE Scott LD Noble J Moloi L Erasmus WD Venter W Stevens 2009 Evaluation of the Abbott m2000 RealTime human immunodeficiency virus type 1 (HIV-1) assay for HIV load monitoring in South Africa compared to the Roche Cobas AmpliPrep-Cobas Amplicor, Roche Cobas AmpliPrep-Cobas TaqMan HIV-1, and BioMerieux NucliSENS EasyQ HIV-1 assays J Clin Microbiol 47 2209 2217 10.1128/JCM.01761-08 19420172
16. J Vingerhoets L Tambuyzer H Azijn A Hoogstoel S Nijs M Peeters, et al. 2010 Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies AIDS 24 4 503 514 1:CAS:528:DC%2BC3cXisFOjur4%3D 10.1097/QAD.0b013e32833677ac 20051805
17. Y Yazdanpanah C Fagard D Descamps AM Taburet C Colin B Roquebert, et al. 2009 High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial Clin Infect Dis 49 1441 1449 1:CAS:528:DC%2BD1MXhsFSqu7%2FP 10.1086/630210 19814627
18. MA Wainberg 2004 The impact of the M184V substitution on drug resistance and viral fitness Expert Rev Anti Infect Ther 2 147 151 1:CAS:528: DC%2BD2cXisFCqtrY%3D 10.1586/14787210.2.1.147 15482179 (Pubitemid 38735755)
19. X Wei C Liang M Gotte MA Wainberg 2002 The M184V mutation in HIV-1 reverse transcriptase reduces the restoration of wild-type replication by attenuated viruses AIDS 16 2391 2398 1:CAS:528:DC%2BD38XptFKgurc%3D 10.1097/00002030-200212060-00003 12461412 (Pubitemid 35471687)
20. S Sierra R Kaiser A Thielen T Lengauer 2007 Genotypic coreceptor analysis Eur J Med Res 12 453 462 1:CAS:528:DC%2BD2sXhsVGitb%2FK 17933727 (Pubitemid 350011458)
21. A Saracino L Monno G Punzi DC Cibelli A Tartaglia L Scudeller, et al. 2007 HIV-1 biological phenotype and predicted coreceptor usage based on V3 loop sequence in paired PBMC and plasma samples Virus Res 130 34 42 1:CAS:528:DC%2BD2sXht12gurbN 10.1016/j.virusres.2007.05.011 17582634 (Pubitemid 350051085)